Device Trial Radar · NCT02107495
Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care Setting
Last checked: Nov 19, 2026Latest source record: Apr 19, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
191
Actual
Start
Mar 2014
Primary completion
Feb 2015
Study completion Feb 2015
Sponsor
- Lead sponsor
- Samsung ElectronicsNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Nexus DX
- First posted
- Apr 8, 2014
Design
- Study type
- Observational
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To establish the performance characteristics of the Samsung LABGEO IVD-A20 CHF Test in intended use settings, by comparing test results of the A20 CHF Test with results obtained from an FDA-cleared comparator assay.
Conditions
- Congestive Heart Failure
Interventions
Samsung LABGEO IVD-A20 CHF TestDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of clinically-confirmed CHF subjects for whom the Samsung LABGEO IVD-A20 CHF Test result was positive (clinical sensitivity).Time frame: baseline
- The proportion of non-CHF subjects for whom the LABGEO IVD A20 CHF Test result was negative (clinical specificity).Time frame: baseline
- Using a Passing-Bablok regression analysis, estimates of intercept and slope will be computed. Estimates of bias and corresponding 95% confidence interval for true bias at clinical decision threshold of 125mg/mL and 450 pg/mL will also be computed.Time frame: baseline
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Maryland
Baltimore, Maryland
Minneapolis Medical Research Foundation
Minneapolis, Minnesota
Manassas Clinical Research Center
Manassas, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.